{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.4","upperLimit":"71.6","value":"52.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Event-free survival (EFS) is defined as the time from diagnosis to the earliest of disease progression/recurrence, second malignancy or death from any cause, or to the date of last follow-up for patients without events. EFS was estimated using the method of Kaplan and Meier. 2-year estimates are reported with 95% CI's.","dispersionType":"95% Confidence Interval","groups":[{"description":"All eligible patients enrolled on the study","id":"OG000","title":"All Eligible Patients (Combination Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"26 patients were enrolled on the protocol, but 1 was deemed ineligible. The ineligible patient is excluded from all analyses.","reportingStatus":"POSTED","timeFrame":"2 years from diagnosis","title":"Event-free Survival (EFS)","type":"PRIMARY","unitOfMeasure":"percent probability"}